Bridges is a new educational podcast miniseries where co-hosts, Dr. Matthew Lunning and Dr. Tara Graff, bring together voices from across the lymphoma care spectrum. Each episode features candid conversations with a diverse range of clinicians, offering practical insights into current topics in lymphoma.
With Dr. Graff practicing in the community setting at Mission Cancer & Blood and Dr. Lunning in academic medicine at the University of Nebraska, Bridges explores the dynamic between academic and community approaches—working to close the gap
and foster collaboration in patient care.
This episode is not meant to be used for medical advice and is intended for educational purposes only. Speakers were compensated by ADC Therapeutics for their time. The views expressed in this series do not reflect the views of the speaker's employer. This podcast may include discussion of investigational agents that may not be applicable or approved in
your country.
Bridges is a new educational podcast miniseries where co-hosts, Dr. Matthew Lunning and Dr. Tara Graff, bring together voices from across the lymphoma care spectrum. Each episode features candid conversations with a diverse range of clinicians, offering practical insights into current topics in lymphoma.
With Dr. Graff practicing in the community setting at Mission Cancer & Blood and Dr. Lunning in academic medicine at the University of Nebraska, Bridges explores the dynamic between academic and community approaches—working to close the gap
and foster collaboration in patient care.
This episode is not meant to be used for medical advice and is intended for educational purposes only. Speakers were compensated by ADC Therapeutics for their time. The views expressed in this series do not reflect the views of the speaker's employer. This podcast may include discussion of investigational agents that may not be applicable or approved in
your country.
Gain practical insights into treatment sequencing in the evolving DLBCL landscape. In this episode, Dr. Marin Xavier shares her approach to navigating novel therapies—such as antibody drug conjugates (ADCs) and bispecifics—with a focus on patients who may not be ready for CAR T-cell therapy. Learn how she makes real-world decisions in a complex and rapidly changing field.
Co-hosts: Dr. Matthew Lunning, MD, University of Nebraska Medical Center, and Dr. Tara Graff, MD, Mission Cancer & Blood
Guest: Dr. Marin Xavier, Hematologist and Oncologist, Scripps Health, San Diego